• Asian Pacific Journal of Cancer Prevention
• /
• 제16권15호
• /
• pp.6673-6679
• /
• 2015

Background: Male breast cancer is a rare neoplasm, and its treatments are based on those of female breast cancer. This study aimed to analyze 20 years of male breast cancer clinical characteristics and treatment results from the Middle Black Sea Region of Turkey. Materials and Methods: A retrospective analysis of 16 male breast cancer patients treated in our tertiary hospital between 1994 and 2014 was performed. Epidemiologic data, tumor characteristics, and treatments were recorded and compared with 466 female breast cancer ((premenopausal; n = 230) + (postmenopausal n = 236)) patients. The 5-year disease-free and overall survival rates were calculated. Results: Male breast cancer constituted 0.1% of all malignant neoplasms in both sexes, 0.2% of all malignant neoplasms in males, and 0.7% of all breast cancers. The mean patient age in this study was $59.8{\pm}9.5$ (39-74) years. The mean time between first symptom and diagnosis was $32.4{\pm}5.3$ (3-60) months. Histology revealed infiltrative ductal carcinoma in 81.3% of patients. The most common detected molecular subtype was luminal A, in 12 (75%) patients. Estrogen receptor rate (93.8%) in male breast cancer patients was significantly higher than that in female breast cancer (70.8% in all females, p = 0.003; 68.2% in postmenopausal females, p = 0.002) patients. Most of the tumors (56.3%) were grade 2. Tumor stage was T4 in 50% of males. The majority (56.3%) of the patients were stage III at diagnosis. Surgery, chemotherapy, radiotherapy and endocrine-therapy were applied to 62.5%, 62.5%, 81.2% and 73.3%, respectively. Loco-regional failure did not occur in any of the cases. All recurrences were metastastic. The 5-year disease-free and overall survival rates in male breast cancer patients were 58% and 68%, respectively. Conclusions: Tumors found in male breast cancer patients were similar in size to tumors found in females, but they advanced to T4 stage more rapidly because of the lack of breast parenchymal tissues. The rate of estrogen receptor expression tended to be higher in male breast cancer patients than in female breast cancer patients. Metastasis is the most important problem in initially non-metastatic male breast cancer patients.

• 대한영상의학회지
• /
• 제83권3호
• /
• pp.687-692
• /
• 2022

남성 유방암은 드물며 유방암의 약 1%를 차지한다. 유방 외 악성 종양이 남성 유방으로의 전이는 매우 드물다. 남자에서 유방으로 전이되는 가장 흔한 원발성 종양은 전립선암, 폐암, 위암, 대장암, 흑색종 및 육종이다. 남자에서 방광암의 유방으로의 전이 유방암은 드물게 보고되었고, 종괴가 아닌 침윤성 소견의 전이 소견을 보이는 경우는 매우 드물다. 방광암이 유방으로 전이된 59세 남자 환자의 유방촬영술 및 초음파에서의 영상 소견을 보고하고자 한다.

• 대한영상의학회지
• /
• 제82권3호
• /
• pp.729-736
• /
• 2021

다발성 원발성 악성 종양은 한 환자에서 2개 이상의 원발성 악성 종양이 각각 독립적으로 발생하는 경우를 말한다. 저자들은 78세 남자 환자에서 동시에 발생한 유방의 점액성 선암과 유방외 림프종의 증례를 경험하여 보고하고자 한다. 환자는 2개의 만져지는 덩이를 주소로 내원하여 외과적 생검을 통해 좌측 유방의 점액성 선암과 우측 서혜부의 미만성 거대 B세포 림프종을 확진하였다. 이후 수술 전 시행한 PET/CT에서 좌측 혀편도의 우연종이 발견되었고, 절제 생검을 통해 미만성 거대 B세포 림프종을 확진하였다. 유방암 환자에서 불특정한 림프절 비대가 발견되는 경우 전이성 병변으로 간주되기 쉬우나, 이 증례의 환자와 같이 고령의 환자군에서는 림프종을 감별 진단으로 함께 고려함으로써 오진 및 치료 지연을 방지할 수 있을 것이다.

• 대한영상의학회지
• /
• 제83권4호
• /
• pp.830-845
• /
• 2022

남성 유방은 기능이 없는 잔유기관이지만, 여성 유방과 유사하게 다양한 질환이 발생할 수 있다. 하지만 여성 유방암과 달리 남성 유방암의 발병률이 낮아 남성 환자를 위한 확립된 검진방법은 없다. 따라서 남성 유방의 평가는 보통 만져지는 종물이나 통증과 같은 증상을 가진 환자에서 진단적 평가를 하게 된다. 더욱이 외래를 방문하는 성인 남성 환자들은 유방뿐 아니라 액와부의 증상을 호소하기도 하며, 일반적으로 유방 초음파 검사 시 유방뿐 아니라 액와까지 검사한다. 이에 본 임상화보는 유방 및 액와의 만져지는 종물을 주소로 내원한 성인 남성 환자에서 발생하였던 다양한 증례의 초음파 소견을 제시하고자 한다.

• 대한영상의학회지
• /
• 제81권6호
• /
• pp.1504-1510
• /
• 2020

이 증례 보고는, 남성 유방에서의 비정형유관증식증 소견에 대한 영상의학적, 병리학적 소견을 담고 있다. 비정형유관증식증은 고위험 병변에 속하며 유방암의 전구 병변으로 잘 알려져 있다. 하지만, 이런 병변이 남성 유방에서 어떠한 임상적 의미를 갖는지는 잘 알려져 있지 않다. 남성 유방은 여성 유방과 달리 유관이 소엽을 구성하지 않기 때문이다. 지금까지 이러한 전구 병변의 영상 소견과 병리학적 소견을 다룬 문헌은 극소수이다. 이 증례 보고를 통해, 우리는 남성 유방에서 유방암 전구 병변의 가능한 영상 및 병리 소견을 제시하고, 문헌고찰을 하고자 한다.

• Journal of Gastric Cancer
• /
• 제13권2호
• /
• pp.126-128
• /
• 2013

Pyogenic liver abscess in patients with malignant disease is a fatal state and is easily diagnosed. We presented a rare case of sudden fatal septicemia following anticancer treatment for recurred gastric cancer due to multiple liver abscesses which could not be diagnosed. A 72-year-old male with recurred gastric cancer received anticancer agents. He had a history of distal gastrectomy with right hepatic lobectomy for hepatic metastasis. He received anticancer treatment in the outpatient's service center periodically, and his performance status was preserved with nothing in particular. After administrating docetaxel, he suddenly developed septicemia and multiple organ failure and died 5 days after strong medical supports. Pathological autopsy revealed that multiple minute abscesses of the liver which could not be detected macroscopically were the causes of fatal septicemia. The etiology, therapies and prognosis of rare entity are being discussed.

• Radiation Oncology Journal
• /
• 제34권2호
• /
• pp.88-95
• /
• 2016

Purpose: The purpose of this study was to estimate the clinical utilization of radiation therapy (RT) in Korea between 2009 and 2013. Materials and Methods: We analyzed open claims data from the Health Insurance Review and Assessment Service. The subjects were patients who had diagnostic codes C00-C97 or D00-D48 according to the 10th revision of the International Classification of Diseases, with procedure codes indicating RT treatment. Results: The total number of patients who received RT in 2009, 2010, 2011, 2012, and 2013 were 45,571, 49,593, 54,671, 59,172, and 61,485, respectively. Among them, the total numbers of male and female patients were 20,780/24,791 in 2009, 22,711/26,882 in 2010, 24,872/29,799 in 2011, 27,101/32,071 in 2012, and 27,941/33,544 in 2013. The five cancers that were most frequently treated with RT between 2009 and 2012 were breast, lung, colorectal, liver, and uterine cervical cancers. However, the fifth most common cancer treated with RT that replaced uterine cervical cancer in 2013 was prostate cancer. The three leading types of cancer among the male patients were lung, colorectal, and liver cancers, whereas in female patients, they were breast, uterine cervical, and lung cancers. The type of cancer most commonly treated by RT was cancer of the central nervous system in patients aged 20 years or less, breast cancer in patients aged 30-50 years, and lung cancer in patients aged 60 years or more. Conclusion: Data from this study provided the clinical utilization of RT in Korea between 2009 and 2013.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권4호
• /
• pp.1501-1506
• /
• 2015

Gemcitabine is an anti-cancer drug with clinically uses in the treatment of various neoplasms, including breast, ovarian, non-small cell lung, pancreaticand cervical cancers, T-cell malignancies, germ cell tumours, and hepatocellular carcinomas. However, it has also been reported to have many adverse effects. Naturally occurring anti-mutagenic effects, especially those of plant origin, have recently become a subject of intensive research. The present study was therefore designed to investigate the anti-mutagenic effects of Salvia merjamie (Family: Lamiaceae) plant extracts against the mutagenic effects of gemcitabine. The anti-mutagenic properties of Salvia merjamie were tested in Inbred SWR/J male and female mice bone marrow cells. The mice were treated in four groups; a control group treated with 30 mg/kg body weight gemcitabine and three treatment groups, each with 30 mg/kg body weight gemcitabine together with, respectively, 50, 100 and 150 mg/kg body weight Salvia merjamie extract. Chromosomal aberration and mitotic index assays were performed with the results demonstrating that Salvia merjamie extract protects bone marrow cells in mice against gemcitabine induced mutagenicity. This information can be used for the development of a potential therapeutic anti-mutagenic agents.

• Asian Pacific Journal of Cancer Prevention
• /
• 제17권2호
• /
• pp.845-849
• /
• 2016

Background: Worldwide, the incidence of cancers is increasing and is becoming a major public health issue, including those in the Asia Pacific region. South-East Asia is a region with diverse populations with different disease spectra. This study looked at the spectrum of cancers among South-East Asians working in Brunei Darussalam. Materials and Methods: The cancer registry from 1994 to 2012 maintained by the State Laboratory was retrospectively reviewed. Crude incidence rates were calculated based on the population census of 2010. Results: Altogether, there was a total of 418 cancer cases diagnosed among South-East Asians, giving an incidence of 5.1% (n=418/8,253). The affected nationals in decreasing frequency were Malaysians (53.1%), followed by Filipinos (25.8%), Indonesians (15.3%), Thais (3.8%), Myanmese (1.7%) and Vietnamese (0.2%) with no recorded cases for Singapore and the People's Republic of Laos. The overall mean age of diagnosis was $46.1{\pm}4.2$ years old, with an increasing trend over the years (p<0.05 ANOVA). The overall gender ratio was 42.3:57.7 (male:female), more females among the Filipinos and Indonesians, more males among the Thais, and equal representation among the Malaysians and the Myanmese. The most common were cancers of the digestive system (19.9%), followed by female reproductive/gynecologic system (16.0%), breast (15.6%), hematological/lymphatic (12.0%) and head/neck (8.1%). There were differences in the prevalence of cancers among the various nationalities with highest crude incidence rate among the Myanmese (141.2/100,000), followed by the Malaysian (88.5/100,000), and the Filipinos (40.6/100,000) and the lowest among the Thais (18.4/100,000), Indonesians (10.5/100,000) and the Vietnamese (6.3/100,000). Conclusions: Cancers among South-East Asian residing in Brunei Darussalam accounted for 5.1% of all cancers. The most common cancers were cancers of the digestive, gynecologic/female reproductive system and breast with certain types slowly increasing in proportions. There mean age of diagnoses was increasing.

• Journal of Preventive Medicine and Public Health
• /
• 제55권6호
• /
• pp.529-538
• /
• 2022

Objectives: This study aimed to identify the current patterns of cancer incidence and estimate the projected cancer incidence and mortality between 2020 and 2035 in Korea. Methods: Data on cancer incidence cases were extracted from the Korean Statistical Information Service from 2000 to 2017, and data on cancer-related deaths were extracted from the National Cancer Center from 2000 to 2018. Cancer cases and deaths were classified according to the International Classification of Diseases, 10th edition. For the current patterns of cancer incidence, age-standardized incidence rates (ASIRs) and age-standardized mortality rates were investigated using the 2000 mid-year estimated population aged over 20 years and older. A joinpoint regression model was used to determine the 2020 to 2035 trends in cancer. Results: Overall, cancer cases were predicted to increase from 265 299 in 2020 to 474 085 in 2035 (growth rate: 1.8%). The greatest increase in the ASIR was projected for prostate cancer among male (7.84 vs. 189.53 per 100 000 people) and breast cancer among female (34.17 vs. 238.45 per 100 000 people) from 2000 to 2035. Overall cancer deaths were projected to increase from 81 717 in 2020 to 95 845 in 2035 (average annual growth rate: 1.2%). Although most cancer mortality rates were projected to decrease, those of breast, pancreatic, and ovarian cancer among female were projected to increase until 2035. Conclusions: These up-to-date projections of cancer incidence and mortality in the Korean population may be a significant resource for implementing cancer-related regulations or developing cancer treatments.